Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cue Biopharma Inc CUE

Healthcare Biotechnology
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease... see more

Recent & Breaking News (NDAQ:CUE)

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

GlobeNewswire April 12, 2023

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

GlobeNewswire March 21, 2023

Cue Biopharma to Host Business Update Call and Webcast

GlobeNewswire March 15, 2023

Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

GlobeNewswire March 1, 2023

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401

GlobeNewswire February 22, 2023

Cue Biopharma's Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

GlobeNewswire February 16, 2023

Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board

GlobeNewswire February 16, 2023

Cue Biopharma to Present at Two February 2023 Scientific Conferences

GlobeNewswire February 1, 2023

Cue Biopharma Announces Chief Medical Officer Transition

GlobeNewswire January 23, 2023

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences

GlobeNewswire November 22, 2022

Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)

Accesswire November 17, 2022

Cue Biopharma Reports Third Quarter 2022 Financial Results

GlobeNewswire November 14, 2022

Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing

GlobeNewswire November 14, 2022

Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GlobeNewswire November 10, 2022

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

GlobeNewswire November 9, 2022

Cue Biopharma to Host Business Update Call and Webcast

GlobeNewswire November 7, 2022

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GlobeNewswire October 5, 2022

Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

GlobeNewswire October 4, 2022

Cue Biopharma to Present at Two September 2022 Scientific Conferences

GlobeNewswire September 7, 2022

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms' Tumor 1 (WT1) - expressing cancers

GlobeNewswire August 22, 2022